Cancer Stem Cell News Volume 3.02 | Jan 22 2014


    Cancer Stem Cell News 3.02 January 22, 2014

    Cancer Stem Cell News

         In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
    Cell Therapy News on Facebook  Cancer Stem Cell News on Twitter

    Proto-Oncogenic Role of Mutant IDH2 in Leukemia Initiation and Maintenance
    Investigators found that isocitrate dehydrogenase (IDH2)R140Q can cooperate with overexpression of HoxA9 and Meis1a and with mutations in FMS-like tyrosine kinase 3 to drive acute leukemia in vivo. [Cell Stem Cell]
    Abstract | Graphical Abstract
    Video Protocol: Mucociliary Differentiation of Primary Bronchial Epithelial Cells

    PUBLICATIONS (Ranked by impact factor of the journal)
    CD133+ Cancer Stem-Like Cells in Small Cell Lung Cancer Are Highly Tumorigenic and Chemoresistant but Sensitive to a Novel Neuropeptide Antagonist
    Researchers characterized the expression of CD133, one important marker of cancer stem-like cells in other cancers, in small cell lung cancer cells. CD133 expression correlated with chemoresistance and increased tumorigenicity in vitro and in vivo accompanied by increased expression of Akt/PKB and Bcl-2. [Cancer Res] Abstract

    Multiple Receptor Tyrosine Kinases Converge on MicroRNA-134 to Control KRAS, STAT5B, and Glioblastoma
    The authors showed that the receptor tyrosine kinases MET, EGFR, and PDGFR regulate microRNA-134 (miR-134) in glioblastoma. They found that miR-134 is downregulated in human tumors and cancer stem cells and that its expression inversely correlates with the activation of MET, EGFR, and PDGFR. [Cell Death Diff] Abstract

    Inhibition of CXCR7 Extends Survival following Irradiation of Brain Tumors in Mice and Rats
    Investigators used neurosphere formation assays with human glioblastoma multiforme xenografts to determine whether CXCR7 is required for cancer stem cell activity in vitro. [Br J Cancer] Abstract

    CD133+ Cells Contribute to Radioresistance via Altered Regulation of DNA Repair Genes in Human Lung Cancer Cells
    The prominin 1 (CD133) cell surface protein is proposed to be a marker enriching for cancer stem cells. Scientists explored the importance of DNA repair in contributing to radioresistance in CD133+ lung cancer cells. [Radiother Oncol] Abstract

    CXCL12 Secreted from Glioma Stem Cells Regulates Their Proliferation
    To provide evidence for establishing a new therapy targeting the CXCL12/CXCR4 pathway, researchers investigated whether CXCL12 secreted from glioma stem cells (GSCs) contributed to their proliferation and promoted angiogenesis in murine GSCs. [J Neurooncol] Abstract

    Phenotypic and Functional Characterization of Glioblastoma Cancer Stem Cells Identified through 5-Aminolevulinic Acid-Assisted Surgery
    Researchers analyzed the phenotype of Glioblastoma (GBM) cells isolated from distinct tumor areas determined by 5-aminolevulinic acid (5-ALA) (tumor core, 5-ALA intense and vague layers) and the potency of 5-ALA labeling in identifying GBM cells and cancer stem cells in the mass. [J Neurooncol] Abstract

    The Impact of Arsenic Trioxide and All-Trans Retinoic Acid on p53 R273H-Codon Mutant Glioblastoma
    The effects of arsenic trioxide (ATO) and all-trans retinoic acid (ATRA), possible targeted treatments of cancer stem cells, were investigated in U87MG neurospheres. The results showed that U87-p53R273H cells generated more rapid neurosphere growth than U87-p53wt but inhibition of neurosphere proliferation was seen with both ATO and ATRA. [Tumor Biol] Abstract

    Ovarian Cancer Stem Cell-Specific Gene Expression Profiling and Targeted Drug Prescreening
    Scientists compared ovarian cancer stem cell (OVCSC) expression profiles in normal ovarian surface epithelium and ovarian cells from patients with advanced disease to identify key pathways and specific molecular signatures involved in ovarian cancer progression and to prescreen candidate small-molecule compounds with anti-OVCSC activity. [Oncol Rep] Abstract

    ZFHX4 Interacts with the Nucleosome Remodeling and Deacetylase Core Member CHD4 and Regulates the Glioblastoma Tumor-Initiating Cell State
    To understand the regulation of the tumor-initiating cell (TIC) state, researchers performed an image-based screen for genes regulating glioblastoma TIC maintenance and identified ZFHX4, a 397 kDa transcription factor. ZFHX4 is required to maintain TIC-associated and normal human neural precursor cell phenotypes in vitro, suggesting that ZFHX4 regulates differentiation, and its suppression increases glioma-free survival in intracranial xenografts. [Cell Rep] Full Article | Graphical Abstract

    Culture Human Glioma-Derived Tumorspheres with NeuroCult™ - View Publications

    The ID Proteins: Master Regulators of Cancer Stem Cells and Tumor Aggressiveness
    The ability of inhibitor of DNA binding (ID) proteins to function as central ‘hubs’ for the coordination of multiple cancer hallmarks has established these transcriptional regulators as therapeutic targets and biomarkers in specific types of human tumors. [Nat Rev Cancer] Abstract

    Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.

    Hear from the leaders in the Cell Culture sector!

    The HUB Foundation for Organoid Technology and STEMCELL Technologies Sign Agreement on the Manufacturing of Cell Culture Media for Organoids
    The HUB Foundation for Organoid Technology announced that it has signed a licensing agreement with STEMCELL Technologies Inc. for the manufacturing and worldwide distribution of cell culture media for growing Organoids. Organoids are mini-organs grown in tissue culture from small pieces of tissue derived from patients with cancer and other diseases, and represent an exciting new tool for scientific research and drug discovery and validation. [STEMCELL Technologies Inc.] Press Release

    Merck Initiates Rolling Submission of U.S. Biologics License Application for MK-3475, an Investigational Anti-PD-1 Immunotherapy, in Patients with Advanced Melanoma
    Merck said it has started a rolling submission to the U.S. Food and Drug Administration of a Biologics License Application for MK-3475, the company’s investigational anti-PD-1 immunotherapy, for patients with advanced melanoma who have been previously treated with ipilimumab. [Merck] Press Release

    From our sponsor: Free human hematopoietic progenitors wallchart. Request your copy.

    National Institutes of Health (United States)

    Food and Drug Administration (United States)

    Center for Biologics Evaluation and Research (United States)

    European Medicines Agency (European Union)

    Medicines and Healthcare Products Regulatory Agency (United Kingdom)

    Therapeutic Goods Administration (Australia)

    NEW Annual Conference of the British Society for Gene and Cell Therapy (BSGCT)
    March 28, 2014
    London, United Kingdom

    Visit our events page to see a complete list of events in the cancer stem cell community.

    NEW Postdoctoral Fellow – Morphogenetic Signaling Pathways in Development and Disease (University of Rochester Medical Center)

    Postdoctoral Research Fellow (Brigham & Women’s Hospital and Harvard Medical School)

    Postdoctoral Position – Epigenetics and Cancer Biology (MPI Bad Nauheim)

    PhD Candidates – Stem Cells and Biomedical Engineering (Queensland University of Technology)

    Senior Research Scientist – Cancer Stem Cell Biology (Aurora Health Care)

    Postdoctoral Position – Stem Cells and Bioengineering (Queensland University of Technology/Translational Research Institute)

    Clinical MD – Clinical Development Program for Oncology and Autoimmune Diseases (Immunomedics, Inc.)

    Chief Medical Officer – Novel Therapeutics in Oncology and Autoimmune Disease (Immunomedics, Inc.)

    Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.


    Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!

    Comments or Suggestions? Email Comments or suggestions? Submit your feedback here

    Learn more about Cancer Stem Cell News: Archives | Events | Contact Us